Chemosensitizing potential of methylglyoxal with metronomic cyclophosphamide in breast cancer therapy: 𝐼𝑛 𝑣𝑖𝑡𝑟𝑜 and 𝑖𝑛 𝑣𝑖𝑣𝑜 evidence

نویسندگان
doi
10.48309/jmpcr.2025.513716.1642
چکیده

Breast cancer, the most prevalent malignancy globally, presents treatment challenges due to drug resistance and chemotherapy-associated toxicity. Metronomic chemotherapy, involving continuous low-dose administration of chemotherapeutic agents, enhances efficacy while minimizing adverse effects. Methylglyoxal (MGO), a reactive dicarbonyl compound with potent anticancer properties, exhibits pro-apoptotic, oxidative stress-modulating, and anti-metastatic effects. This study explores MGO's potential as a chemosensitizer in combination with metronomic cyclophosphamide in breast cancer models. In vitro , MGO showed dose-dependent cytotoxicity in MCF-7 and MDA-MB-231 cells, with heightened sensitivity in MDA-MB-231 cells. Combination treatment significantly increased reactive oxygen species (ROS) generation and apoptosis in both cell lines. In vivo , combination therapy achieved substantial tumor regression, with one regimen reducing tumor volume by 91.8%. Treatment also restored antioxidant enzyme activity and reduced serum cancer marker enzymes. These findings demonstrate MGO's potential as a chemo-sensitizing agent that enhances metronomic cyclophosphamide's efficacy by modulating tumor growth, apoptosis, oxidative stress, and metastasis. Further research into its molecular mechanisms and clinical applications could yield a promising strategy for breast cancer therapy.